![](https://monteverdelaw.com/wp-content/uploads/images.png)
ARCA Biopharma, Inc. (Nasdaq: ABIO), relating to its proposed sale to Oruka Therapeutics. Under the terms of the agreement, ABIO shareholders are expected to own approximately 2.38% of the combined company.
ARCA Biopharma, Inc. (Nasdaq: ABIO), relating to its proposed sale to Oruka Therapeutics. Under the terms of the agreement, ABIO shareholders are expected to own approximately 2.38% of the combined company.